This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

MediciNova Releases Notice Of Pendency And Settlement Of Class Action

MediciNova, Inc., a biopharmaceutical company publicly traded on the Nasdaq Global Market (NASDAQ: MNOV) and the Hercules Market of the Osaka Securities Exchange (OSAKA: 4875), today releases the notice of pendency and settlement of class action seen below:

 
SUPERIOR COURT FOR THE STATE OF CALIFORNIA
 

FOR THE COUNTY OF ALAMEDA

 
THE PENNSYLVANIA AVENUE FUNDS, individually and on behalf of all others similarly situated,
Case No. RG09470224
 
NOTICE OF PENDENCY AND SETTLEMENT OF CLASS ACTION
Plaintiff,
 
v. EXHIBIT A-1
 
 
AVIGEN, INC.; ZOLA HOROVITZ; JOHN K.A. PRENDERGAST; KENNETH CHAHINE; RICHARD WALLACE; JAN K. ÖHRSTRÖM; STEPHEN G. DILLY; MEDICINOVA, INC.
 
Defendants.
 

This notice (the “Notice”) provides you with important information in connection with the settlement (the “Settlement”) of a civil action concerning the acquisition of Avigen, Inc. (“Avigen”) by MediciNova, Inc. (“MediciNova”). Your legal rights may be affected by this Notice and the proceedings in this litigation, whether you act or do not act. You should read this Notice carefully.

  • This Notice is dated April 23, 2010 (the “Notice Date”).
  • This Notice is being published pursuant to an Order of the Superior Court of California, Alameda County, granting preliminary approval of the Stipulation of Settlement (the “Stipulation”), dated March 11, 2010, by and among the Settling Parties (defined below). This is not a solicitation from a lawyer.
  • The Settlement resolves a case filed in this Court as a proposed class action (the “Action”) that raised the issues of whether the directors of Avigen fulfilled their fiduciary duties to the stockholders of Avigen when Avigen entered into a merger agreement with MediciNova (the “Transaction”), including whether the Forms S-4 as amended filed with the Securities and Exchange Commission (the “SEC”) on September 17, 2009 and October 23, 2009, provided adequate disclosures to the stockholders of Avigen with regard to the Transaction.
  • The Settlement provides for the disclosure of additional information by Avigen and MediciNova. Plaintiff believes the disclosure of such information was necessary in order for Avigen shareholders to make an informed vote on the Transaction. Defendants do not believe that any additional disclosures were necessary.
  • Your legal rights and options are explained in this Notice.
  • The Court in charge of this case must decide whether to approve the Settlement.

BASIC INFORMATION

1. Why Did I Get This Notice?

You or someone in your family may have held shares of Avigen common stock at some time from August 20, 2009 through and including December 18, 2009, the Closing Date as defined in the Agreement and Plan of Merger between Avigen and MediciNova (the “Merger Agreement”).

1 of 8

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs